One of the leading clinical-stage oncology companies, Prescient Therapeutics Limited (ASX:PTX), has been making its way through the year 2021 with great progression in clinical…

Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year 2022. The ASX-listed clinical stage oncology company continues to stand…

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8 million in…

Summary Prescient Therapeutics (ASX:PTX): We spoke with Steve Yatomi-Clarke, CEO of Prescient Therapeutics, about the exciting new world of CAR-T therapy for the treatment of cancer and…

Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021. Steven introduced Prescient Therapeutics to a new range of investors,…

Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies as the company builds towards clinical testing. These studies –…

(ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell and Gene Meeting in the US. The company said the new results demonstrate the…

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its OmniCAR cell therapy technology in killing multiple cancer cells.

Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting the attention of leading global therapy decision makers.

Biotech company Prescient Therapeutics has given investors a glimpse into the progress of it’s next-generation CAR-T platform, OmniCAR , with data to be presented at…